

28. The pharmaceutical composition of claim 27, wherein said additional therapeutic agent is selected from ribavirin, an NS3 protease inhibitor, a nucleoside or nucleotide inhibitor of HCV NS5B polymerase, an alpha-glucosidase 1 inhibitor, a hepatoprotectant, a non-nucleoside inhibitor of HCV polymerase, or combinations thereof.


29. The pharmaceutical composition according to claim 25, further comprising a nucleoside or nucleotide inhibitor of HCV NS5B polymerase.

30. The pharmaceutical composition according to claim 29, wherein said nucleoside or nucleotide inhibitor of HCV NS5B polymerase is selected from ribavirin, viramidine, levovirin, a L-nucleoside, or isatoribine.

31. A pharmaceutical composition comprising a compound as in claims 1-24, at least one nucleoside or nucleotide inhibitor of HCV NS5B polymerase, and at least one pharmaceutically acceptable carrier.

32. The pharmaceutical composition according to claim 31, further comprising an interferon, a pegylated interferon, ribavirin or combinations thereof.

33. The pharmaceutical composition of claim 31 or claim 32, wherein the compound is of the formula



34. The pharmaceutical composition of any one of claims 31-33, wherein the nucleoside or nucleotide inhibitor of HCV NS5B polymerase is sofosbuvir.

35. A method of treating hepatitis C, said method comprising administering to a human patient a pharmaceutical composition which comprises a therapeutically effective amount of the compound as described in any of claims 1-24 or a pharmaceutically acceptable salt, or prodrug thereof.

36. The method according to claim 35, further comprising administering to the patient an interferon or pegylated interferon.

~~37. The method according to claim 35 or claim 36, further comprising administering to the patient ribavirin.~~

~~38~~35. A compound as described in any of claims 1-24 or a pharmaceutically acceptable salt, or prodrug thereof for use in medical therapy.

~~39~~36. Use of a compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt, or prodrug thereof for preparing a medicament for treating hepatitis C or a hepatitis C associated disorder in an animal.

~~40~~37. A compound as described in any of claims 1-24 or a pharmaceutically acceptable salt, or prodrug thereof for use in the prophylactic or therapeutic treatment of hepatitis C or a hepatitis C associated disorder.

~~41. A novel compound as described herein.~~

~~42. A novel synthetic method as described herein.~~

38. The use of claim 36, wherein the medicament is to be administered with an interferon or pegylated interferon.

39. The use of claim 36 or 37, wherein the medicament is to be administered with ribavirin.

40. The compound of claim 37, wherein the compound is to be administered with an interferon or pegylated interferon.

41. The compound of claim 37 or 40, wherein the compound is to be administered with ribavirin.